Lucid Diagnostics, a medtech company with ties to Case Western Reserve University, plans to go public


Lucid Diagnostics Inc., an esophageal cancer test-maker that uses technology developed at Case Western Reserve University, has filed for an initial public offering valued at up to $57.5 million.

The number of shares to be offered and the price range for the offering have not yet been determined. Lucid Diagnostics, a majority-owned subsidiary of New York-based medical technology company PAVmed Inc. (Nasdaq: PAVM), said in a news release that it intends to list its common stock on the Nasdaq Stock Market under the ticker symbol “LUCD.” (You can go here to read the IPO filing with the U.S. Securities and Exchange Commission.) Joint bookrunning managers for the offering are Cantor Fitzgerald and Canaccord Genuity, and BTIG and Needham are the co-lead managers.

Click here to read the complete story.

Story excerpt provided by Crain’s Cleveland Business.

Written by Scott Suttell.

Originally published September 24, 2021.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: